MEDICA GROUP PLC financials
MEDICA GROUP PLC
213800B8XE5FUSZF5Z16 | Line item | 2022 | 2021 |
|---|---|---|
| Income statement | ||
| Revenue | £77.0M | £61.9M |
| Cost of sales | £39.8M | £30.5M |
| Gross profit | £37.2M | £31.4M |
| Administrative expenses | £28.7M | £22.9M |
| Operating profit (EBIT) | £8.5M | £8.5M |
| Finance costs | £840.0K | £1.1M |
| Profit before tax | £8.6M | £7.3M |
| Income tax expense | £1.4M | £1.9M |
| Profit for the year | £7.2M | £5.5M |
| — attributable to owners | £7.2M | £5.5M |
| Total comprehensive income | £7.8M | £5.3M |
| Per share | ||
| Basic EPS | £0.06 | £0.05 |
| Diluted EPS | £0.06 | £0.04 |
| Free cash flow / share | £0.06 | £0.07 |
| Cash flow statement | ||
| Net cash from operating activities | £8.7M | £9.7M |
| Net cash from investing activities | -£7.8M | -£13.5M |
| Purchase of PP&E (capex) | £1.8M | £1.3M |
| Purchase of intangibles | £1.1M | £763.0K |
| Net cash from financing activities | £312.0K | -£303.0K |
| Dividends paid | £3.3M | £3.2M |
| Proceeds from borrowings | £8.3M | £11.6M |
| Repayments of borrowings | £4.0M | £23.5M |
| Lease liability payments | £333.0K | £407.0K |
| Net change in cash | £1.2M | -£4.1M |
| Balance sheet | ||
| Total assets | £86.2M | £81.3M |
| Non-current assets | £57.4M | £57.5M |
| Property, plant & equipment | £4.5M | £4.5M |
| Intangible assets & goodwill | £31.1M | £30.4M |
| Current assets | £28.8M | £23.9M |
| Trade & other receivables | £17.8M | £14.3M |
| Cash & equivalents | £11.0M | £9.6M |
| Total equity | £61.1M | £54.9M |
| Non-current liabilities | £7.9M | £4.6M |
| Long-term borrowings | £5.7M | £0 |
| Lease liabilities (non-current) | £701.0K | £814.0K |
| Current liabilities | £17.2M | £21.8M |
| Short-term borrowings | £4.5M | £5.7M |
| Lease liabilities (current) | £253.0K | £280.0K |
| Trade & other payables | £9.9M | £9.6M |
| Deferred tax liabilities | £1.5M | £2.3M |
| Derived metrics | ||
| Free cash flow | £7.0M | £8.4M |
| Operating margin | 11.0% | 13.8% |
| Net margin | 9.4% | 8.8% |
| Return on equity | 11.8% | 10.0% |
| Cash conversion ratio | 1.21× | 1.78× |
| Capex coverage | 4.94× | 7.42× |
| Other reported items | ||
| Adjustments For Amortisation Expense | £3.0M | £2.8M |
| Adjustments For Decrease Increase In Trade and Other Receivables | -£1.9M | -£4.7M |
| Adjustments For Depreciation Expense | £1.9M | £1.7M |
| Adjustments For Fair Value Gains Losses | -£1.0M | £0 |
| Adjustments For Finance Costs | £840.0K | £1.1M |
| Adjustments For Finance Income | £1.1M | £0 |
| Adjustments For Increase Decrease In Employee Benefit Liabilities | £92.0K | £78.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | -£1.3M | £2.8M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | £29.0K | £55.0K |
| Adjustments For Sharebased Payments | £1.7M | £682.0K |
| Adjustments For Undistributed Profits of Investments Accounted For Using Equity Method | -£112.0K | -£56.0K |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -£252.0K | -£590.0K |
| Assets Less Current Liabilities | £69.0M | £59.5M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | £0 | £11.4M |
| Current Assets Liabilities | £11.6M | £2.1M |
| Current Tax Liabilities Current | £1.0M | £880.0K |
| Decrease Increase Through Tax On Sharebased Payment Transactions | -£18.0K | £33.0K |
| Deferred Tax Assets | £556.0K | £186.0K |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners | £2.3M | — |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | £0.02 | — |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | £172.0K | -£236.0K |
| Finance Income | £1.1M | £0 |
| Income Taxes Paid Refund Classified As Operating Activities | £1.9M | £1.6M |
| Increase Decrease Through Sharebased Payment Transactions | £1.7M | £682.0K |
| Increase Decrease Through Transactions With Owners | -£1.6M | £13.1M |
| Intangible Assets Other Than Goodwill | £21.2M | £22.4M |
| Interest Paid Classified As Financing Activities | £350.0K | £424.0K |
| Interest Received Classified As Investing Activities | £0 | £0 |
| Investments In Joint Ventures Accounted For Using Equity Method | £57.0K | £0 |
| Issue of Equity | £6.0K | £15.6M |
| Issued Capital | £245.0K | £245.0K |
| Net Assets Liabilities | £61.1M | £54.9M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | £590.0K | -£124.0K |
| Payments For Share Issue Costs | £0 | £537.0K |
| Proceeds From Issuing Shares | £6.0K | £16.2M |
| Purchase of Interests In Investments Accounted For Using Equity Method | £169.0K | £0 |
| Reserve of Exchange Differences On Translation | £468.0K | -£122.0K |
| Retained Earnings | £30.0M | £24.5M |
| Share of Profit Loss of Joint Ventures Accounted For Using Equity Method | -£112.0K | -£56.0K |
| Share Premium | £30.3M | £30.3M |
Every line item above is a fact tagged in MEDICA GROUP PLC's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (GBP), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.